Non small lung cancer (NSCLC) is a biologically diverse type of lung cancer driven by a wide array of molecular alterations. Human epidermal growth factor receptor 2 (HER2) alterations occur in approximately 4% of patients with NSCLC and include gene mutations, gene amplifications, and protein overexpression. HER2-targeted therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, have shown promising efficacy for patients with limited treatment options. Testing for HER2 alterations is crucial in order to identify patients who may benefit from targeted therapies, and interprofessional collaboration is critical to optimizing timely diagnosis and personalized management throughout the care continuum (Ismail et al, 2025). In this activity, Maria E. Arcila, MD, Attending Physician and Deputy Chief of the Molecular Diagnostics Service in the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, and Helena A. Yu, MD, Attending Physician and Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center, will explore strategies for closing the gap between detection and optimal treatment in NSCLC with HER2 alterations.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 3775 Sixth Avenue
Pricing
96% of listed courses are free
25 of 26 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Communication & Shared Decision-Making
- Endocrinology, Diabetes & Metabolism
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Gynecologic Oncology
- Hematology
- Hospice & Palliative Medicine
- Medical Oncology
- Nephrology
- Pediatric Emergency Medicine
- Pediatric Hematology-Oncology
- Rheumatology
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
ReleasedFeb 9, 2026
-
Last day to claim creditFeb 9, 2027 4 months left
-
University of Chicago School of Medicine Strategies for Improving ERBB2 (HER2) Testing in NSCLC Within Community Settings
-
Medscape, LLC Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC
-
LUNGevity Foundation +1 Mastering the Breakthroughs in HER2-Mutant NSCLC: Decoding Alterations, Refining Treatment, and Empowering Patients
-
i3 Health HER2-Mutant NSCLC Virtual Tumor Board: Applying Advances and Best Practices in the Community Setting
-
i3 Health Virtual Tumor Board Challenge: Navigating Treatment Selection and Sequencing in Metastatic Prostate Cancer
-
i3 Health Progressive Familial Intrahepatic Cholestasis (PFIC) in Adults: Deciphering the Role of Genetics in Diagnosis and Treatment
